Literature DB >> 19265196

Differential behavior of missense mutations in the intersubunit contact domain of the human pyruvate kinase M2 isozyme.

Kamal Akhtar1, Vibhor Gupta, Anita Koul, Neelima Alam, Rajiv Bhat, Rameshwar N K Bamezai.   

Abstract

In this study, we attempted to understand the mechanism of regulation of the activity and allosteric behavior of the pyruvate kinase M(2) enzyme and two of its missense mutations, H391Y and K422R, found in cells from Bloom syndrome patients, prone to develop cancer. Results show that despite the presence of mutations in the intersubunit contact domain, the K422R and H391Y mutant proteins maintained their homotetrameric structure, similar to the wild-type protein, but showed a loss of activity of 75 and 20%, respectively. Interestingly, H391Y showed a 6-fold increase in affinity for its substrate phosphoenolpyruvate and behaved like a non-allosteric protein with compromised cooperative binding. However, the affinity for phosphoenolpyruvate was lost significantly in K422R. Unlike K422R, H391Y showed enhanced thermal stability, stability over a range of pH values, a lesser effect of the allosteric inhibitor Phe, and resistance toward structural alteration upon binding of the activator (fructose 1,6-bisphosphate) and inhibitor (Phe). Both mutants showed a slight shift in the pH optimum from 7.4 to 7.0. Although this study signifies the importance of conserved amino acid residues in long-range communications between the subunits of multimeric proteins, the altered behavior of mutants is suggestive of their probable role in tumor-promoting growth and metabolism in Bloom syndrome patients with defective pyruvate kinase M(2).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265196      PMCID: PMC2673266          DOI: 10.1074/jbc.M808761200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL.

Authors:  J MONOD; J WYMAN; J P CHANGEUX
Journal:  J Mol Biol       Date:  1965-05       Impact factor: 5.469

2.  Six previously undescribed pyruvate kinase mutations causing enzyme deficiency.

Authors:  A Demina; K I Varughese; J Barbot; L Forman; E Beutler
Journal:  Blood       Date:  1998-07-15       Impact factor: 22.113

3.  Conversion of non-allosteric pyruvate kinase isozyme into an allosteric enzyme by a single amino acid substitution.

Authors:  Y Ikeda; T Tanaka; T Noguchi
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

4.  Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis.

Authors:  Jill D Dombrauckas; Bernard D Santarsiero; Andrew D Mesecar
Journal:  Biochemistry       Date:  2005-07-12       Impact factor: 3.162

5.  Allosteric regulation of pyruvate kinase M2 isozyme involves a cysteine residue in the intersubunit contact.

Authors:  Y Ikeda; T Noguchi
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

6.  Molecular modelling of human red blood cell pyruvate kinase: structural implications of a novel G1091 to a mutation causing severe nonspherocytic hemolytic anemia.

Authors:  W W van Solinge; R J Kraaijenhagen; G Rijksen; R van Wijk; B B Stoffer; M Gajhede; F C Nielsen
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

7.  Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein.

Authors:  W Zwerschke; S Mazurek; P Massimi; L Banks; E Eigenbrodt; P Jansen-Dürr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Allostery in rabbit pyruvate kinase: development of a strategy to elucidate the mechanism.

Authors:  R H Friesen; R J Castellani; J C Lee; W Braun
Journal:  Biochemistry       Date:  1998-11-03       Impact factor: 3.162

9.  The negative dominant effects of T340M mutation on mammalian pyruvate kinase.

Authors:  R H Friesen; J C Lee
Journal:  J Biol Chem       Date:  1998-06-12       Impact factor: 5.157

10.  How to measure and predict the molar absorption coefficient of a protein.

Authors:  C N Pace; F Vajdos; L Fee; G Grimsley; T Gray
Journal:  Protein Sci       Date:  1995-11       Impact factor: 6.725

View more
  13 in total

Review 1.  Human pyruvate kinase M2: a multifunctional protein.

Authors:  Vibhor Gupta; Rameshwar N K Bamezai
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

Review 2.  Dysregulated pH: a perfect storm for cancer progression.

Authors:  Bradley A Webb; Michael Chimenti; Matthew P Jacobson; Diane L Barber
Journal:  Nat Rev Cancer       Date:  2011-08-11       Impact factor: 60.716

Review 3.  Pyruvate kinase: Function, regulation and role in cancer.

Authors:  William J Israelsen; Matthew G Vander Heiden
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

4.  Cancer-associated mutations in human pyruvate kinase M2 impair enzyme activity.

Authors:  Vivian M Liu; Andrea J Howell; Aaron M Hosios; Zhaoqi Li; William J Israelsen; Matthew G Vander Heiden
Journal:  FEBS Lett       Date:  2019-11-16       Impact factor: 4.124

5.  Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy.

Authors:  Vibhor Gupta; Ponnusamy Kalaiarasan; Mohammad Faheem; Nishant Singh; Mohammad Askandar Iqbal; Rameshwar N K Bamezai
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

6.  Missense mutations in pyruvate kinase M2 promote cancer metabolism, oxidative endurance, anchorage independence, and tumor growth in a dominant negative manner.

Authors:  Mohd Askandar Iqbal; Farid Ahmad Siddiqui; Noor Chaman; Vibhor Gupta; Bhupender Kumar; Prakasam Gopinath; Rameshwar N K Bamezai
Journal:  J Biol Chem       Date:  2014-02-03       Impact factor: 5.157

7.  Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.

Authors:  Dipok Kumar Dhar; Steven W M Olde Damink; James Hal Brindley; Andrew Godfrey; Michael H Chapman; Neomal S Sandanayake; Fausto Andreola; Sybille Mazurek; Tayyaba Hasan; Massimo Malago; Stephen P Pereira
Journal:  Cancer       Date:  2012-08-01       Impact factor: 6.860

8.  Functional cross-talk between allosteric effects of activating and inhibiting ligands underlies PKM2 regulation.

Authors:  Jamie A Macpherson; Alina Theisen; Laura Masino; Louise Fets; Paul C Driscoll; Vesela Encheva; Ambrosius P Snijders; Stephen R Martin; Jens Kleinjung; Perdita E Barran; Franca Fraternali; Dimitrios Anastasiou
Journal:  Elife       Date:  2019-07-02       Impact factor: 8.713

9.  Damaged mitochondria in Fanconi anemia - an isolated event or a general phenomenon?

Authors:  Giovanni Pagano; Pavithra Shyamsunder; Rama S Verma; Alex Lyakhovich
Journal:  Oncoscience       Date:  2014-04-21

10.  In silico screening, genotyping, molecular dynamics simulation and activity studies of SNPs in pyruvate kinase M2.

Authors:  Ponnusamy Kalaiarasan; Bhupender Kumar; Rupali Chopra; Vibhor Gupta; Naidu Subbarao; Rameshwar N K Bamezai
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.